Industry Focus Transcripts

If you’re interested in learning more about the Dodd-Frank Act of 2010, then this is the podcast episode for you.

We welcome financials analyst Gaby Lapera to the show to share some of our favorite stocks in the consumer and retail sector. In this case, we have two leading companies in their respective industries that can still make for a David and Goliath story.

Here are the highlights from Warren Buffett and Charlie Munger’s annual Q&A session at Berkshire Hathaway’s yearly gathering.

Some industries might be ripe for disruption, but there is at least one business where moats still have their place.

Two great stocks in the financials sector face off against each other.

We run through a few different tips to make your resolutions easier to hit in 2017 and talk about why we're focusing on doing more stock research, checking out credit cards, and changing our online passwords.

Biotech is risky business, and Incyte shareholders have not had a good week after a key drug flopped its phase 3.

The healthcare sector had a rough time in 2016. This year, we hope it can make some changes that’ll turn its luck around.

Our cast discuss their financial New Year's Resolutions, and check the scoreboard on 12 predictions Jordan Wathen made for BDCs in 2016.

Approximately half of Americans set goals for themselves at the beginning of each year.

A system that could revolutionize gene research and a first-in-class cancer therapy could be two of healthcare's biggest advances this year. Plus, UnitedHealth's earnings review, and a preview of Johnson & Johnson's earnings.

U.S. oil production has bottomed out and is on the upswing -- here’s what you need to know to position your portfolio the right way.

We’re just a few days into OPEC’s production cut, and American oil companies and investors are already responding -- here's what you need to know.

How to build a profit-friendly stock watch list. Plus, Trump’s tough talk on drug costs and why it’s so important to pay off your credit card debt ASAP.

It was a mixed bag for the nation's biggest banks last quarter.

We run through a framework for analyzing companies, and we put Facebook through the wringer. Is it a buy?

We discuss the pros and cons for J&J’s latest quarterly results, plus Alkermes gets a do-over and Celldex flops.

Just because a stock has a high yield doesn’t make it a good dividend stock.

Discover how to use stock screeners to get out of your comfort zone and explore new companies.

International healthcare stocks could be a great fit for your portfolio.